Features of the policy for the development of state control over pharmaceutical production in modern Russia

The article reveals the policy of development of state control over pharmaceutical production in the Russian Federation at the present stage. The author reveals the concept of control and supervisory activities and defines them as identical based on the goals set for these concepts and methods for achieving them. The principles underlying control and supervisory activities are identified, which are divided into general and special based on belonging to one or more industries. Decomposition of the totality of legal acts regulating the industry of activity is carried out to a separate regulatory requirement, which is defi ned as a measured unit of compliance with legal norms. The main threats existing at this stage in the pharmaceutical industry, as well as mechanisms aimed at countering these threats, are considered. The experience and problems of introducing control and accounting labeling of medicines in Russia during the COVID-19 pandemic are considered. The author analyzes experience of the annual operation Pangea XIV, carried out jointly by health authorities and law enforcement agencies of several countries and aimed at combating the production and traffi cking of counterfeit medicines and medical devices around the world, and also reviews law enforcement under articles related to off enses in the fi eld of production and sales of pharmaceuticals. As a result, there is an increase in the number of off enses in the pharmaceutical industry, and there is an increasing role of information technology in the production and sale of counterfeit pharmaceutical products. At the end of the article, a conclusion is formulated, which lists the main directions for improving control and supervisory activities in the Russian Federation at the present stage. The main means of developing control and supervisory activities is the digitalization of the industry, the main tools of which are development of relevant registers of regulatory requirements and control and accounting labeling of medicines.